The bill seeks to legalize therapeutic psilocybin for individuals suffering from specific mental health conditions, including post-traumatic stress disorder, anxiety, depression, and substance use disorders. It establishes a regulatory framework for the cultivation, manufacture, possession, distribution, and administration of psilocybin, which must occur in licensed treatment centers under the supervision of certified clinicians. The legislation outlines the certification process for patients and licensing for practitioners, while also ensuring safety and security standards at treatment facilities. Legal protections are provided for certified patients and licensees, safeguarding them from arrest or penalties related to their authorized use of psilocybin. Additionally, the bill amends existing laws concerning dangerous drugs to include exceptions for therapeutic psilocybin, thereby clarifying its legal status.

Moreover, the bill introduces new sections to Title 50, effective upon passage, and establishes a termination date for its provisions on June 30, 2027. It also addresses the production and manufacture of dangerous drugs, particularly marijuana and tetrahydrocannabinol, by instituting penalties for unlicensed production, with imprisonment terms ranging from 5 to 25 years based on the quantity involved. However, practitioners and their agents acting within their professional scope are exempt from these penalties. The bill mandates annual reporting on certified patients and treatment outcomes, and it creates a special revenue account to manage fees and fines collected under its provisions, which will support the therapeutic psilocybin program's administration.

Statutes affected:
Introduced: 45-9-101, 45-9-102, 45-9-103, 45-9-110, 45-10-107